OR WAIT null SECS
June 01, 2020
The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.
The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.
May 21, 2020
The companies have formed a collaboration to develop a novel human recombinant protein as a therapeutic candidate against COVID-19.
CanSinoBIO will license-in Precision NanoSystems' proprietary RNA vaccine platform technology while the latter leads the development of the RNA vaccine formulation.
May 19, 2020
Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.
May 15, 2020
As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.
Single-use processing requires instruments providing the accuracy of traditional technologies but configured in form factors designed specifically for this service
A variety of assays should be used to detect bacterial, fungal, and viral contaminants in the human source cells used for cell therapies.
May 14, 2020
Santen Pharmaceutical has concluded a licensing agreement with jCyte for the development, registration, and commercialization rights to jCell, an investigational retinitis pigmentosa therapy, in Japan, Asia, and Europe.
May 05, 2020
Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.